#Sweden #Stockholm #Leqembi #BioArctic #Alzheimer’s Disease

BioArctic's Third Quarter Report (July - September 2025)

BioArctic, a Swedish biopharmaceutical company, recently released its interim report for the third quarter of 2025, showcasing noteworthy advancements in its projects and partnerships, especially concerning its flagship Alzheimer's treatment, Leqembi® (lecanemab). This report highlights not just clinical success but also a strategic collaboration that signals strong future potential for innovative therapies.

Key Developments During Q3 2025

The period was notable for numerous significant updates:
1. Lecanemab Advances: At the AAIC Congress, BioArctic presented new data on lecanemab, focusing on its long-term efficacy, safety, real-world evidence, and subcutaneous dosing options. This is crucial for Alzheimer’s treatment, given the growing need for effective therapies in this area.
2. New Collaborations: BioArctic signed a collaboration agreement with Novartis, receiving an initial payment of USD 30 million. This agreement involves a potential treatment that combines BioArctic's proprietary BrainTransporter technology with an undisclosed Novartis antibody. Such alliances are pivotal, enabling sharing of resources and expertise.
3. Regulatory Approvals: The US FDA granted approval for weekly subcutaneous maintenance treatment with Leqembi Iqlik™, signifying an important step in making the drug more accessible. It also received approvals in various other regions, including Australia, Bahrain, and parts of the Middle East.
4. Financial Performance: BioArctic’s financial summaries reflect a robust upward trend in revenue, with net revenues of SEK 133.3 million—primarily from Leqembi royalties. Although operating losses were reported, the overall cash flow improved compared to previous quarters.

CEO Commentary

Gunilla Osswald, CEO of BioArctic, expressed enthusiasm regarding these advancements: "Our collaboration with Novartis marks an exciting new chapter for BioArctic. We have reached several important milestones this quarter, underlining our commitment to innovative solutions that can significantly impact patients' lives."

She emphasized the increasing global establishment of Leqembi as a treatment option for Alzheimer’s disease, noting a 14% quarter-on-quarter growth in sales, adjusted for stock effects seen in China’s market earlier this year. With approvals in over 50 countries, including Canada and Finland, the reach of Leqembi continues to expand impressively.

Future Directions and Research Pipeline

Looking forward, BioArctic plans to drive further development in its pipeline, particularly in exploring treatments using its BrainTransporter technology, not only for Alzheimer’s but also for other neurodegenerative diseases like Huntington’s disease. The company is optimistic, as it continues to seek out innovative modalities that could revolutionize treatment paths. Current projects in clinical trials include options for alpha-synuclein and TDP-43, with results anticipated in the coming years.

Conclusion

BioArctic’s third-quarter report underscores its strategic positioning in the biopharmaceutical industry with a diversified pipeline, promising partnerships, and significant advancements in treatments for Alzheimer’s disease. The company remains committed to improving the lives of patients through continued innovation and collaboration. In an outlook laden with potential, they invite stakeholders to stay engaged as they navigate through the complexities of neurodegenerative disease therapies.

For investors, analysts, and members of the media, BioArctic will host an audiocast presentation detailing the findings and next steps following the publication of the report. This will provide an opportunity for interested parties to engage with the company's leadership team and understand their strategic vision moving forward.